@article{JTD25665,
author = {Paul Hofman},
title = {PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes…does more harm than good!},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {Suppl 3},
year = {2018},
keywords = {},
abstract = {Despite the major advances in treatment of lung carcinomas, in particular of advanced or metastatic non-small cell lung carcinomas (NSCLC) with immunotherapies, a high number of patients do not benefit from this effective treatment. These patients either do not express a sufficient level of biomarkers of companion or complementary tests [PD-L1 and tumor mutational burden (TMB)] for anti-PD1/PD-L1 treatments, or, do not respond to immunotherapies and even worse have a rapid progression of their tumor.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/25665}
}